Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $102.33 Consensus Target Price from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average recommendation of “Hold” by the twenty-four brokerages that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $100.70.

Several research firms recently weighed in on ZBH. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Wells Fargo & Company cut their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Citigroup decreased their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. Finally, Stifel Nicolaus dropped their price target on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research report on Wednesday, April 29th.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $90.13 on Thursday. The stock has a market capitalization of $17.44 billion, a P/E ratio of 23.41, a P/E/G ratio of 2.68 and a beta of 0.46. The company’s fifty day moving average price is $86.79 and its 200 day moving average price is $89.80. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet has a 1 year low of $79.12 and a 1 year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities research analysts anticipate that Zimmer Biomet will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.28% of the stock is owned by company insiders.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently bought and sold shares of ZBH. Tema ETFs LLC lifted its stake in Zimmer Biomet by 39.8% in the 2nd quarter. Tema ETFs LLC now owns 4,194 shares of the medical equipment provider’s stock worth $361,000 after purchasing an additional 1,194 shares in the last quarter. Kentucky Trust Co increased its holdings in shares of Zimmer Biomet by 285.0% in the second quarter. Kentucky Trust Co now owns 770 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 570 shares during the last quarter. Handelsbanken Fonder AB increased its holdings in shares of Zimmer Biomet by 22.7% in the second quarter. Handelsbanken Fonder AB now owns 152,064 shares of the medical equipment provider’s stock valued at $13,091,000 after purchasing an additional 28,130 shares during the last quarter. Valeo Financial Advisors LLC lifted its position in Zimmer Biomet by 1.6% during the second quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock worth $962,000 after buying an additional 175 shares in the last quarter. Finally, Wilsey Asset Management Inc. boosted its stake in Zimmer Biomet by 4.7% during the second quarter. Wilsey Asset Management Inc. now owns 421,867 shares of the medical equipment provider’s stock worth $36,318,000 after buying an additional 18,883 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.